Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators

Pandion Therapeutics has signed a license and collaboration deal worth up to $790m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmune diseases of the pancreas.